Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens
Pathogens · 2024
DOI: 10.3390/pathogens13030248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Aleksandra Górzyńska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology and Parasitology, Wroclaw Medical University, 50-556 Wroclaw, Poland. Hauptthemen laut MEDLINE: Antifungal Agents, Microbial Sensitivity Tests, Saccharomyces cerevisiae, Amphotericin B. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.
Abstract (Originalsprache)
(1)
Background
Despite being considered a non-pathogenic yeast, recently, a growing occurrence of Saccharomyces cerevisiae infections has been noted. There is little knowledge about the drug susceptibility of this species. Therefore, the objective of this research was to expand it and determine the drug susceptibility profile of a local collection of clinical isolates of this species. (2)
Methods
This study contained 55 clinical isolates identified as Saccharomyces cerevisiae using the MALDI-TOF method. The susceptibility of Saccharomyces cerevisiae was tested to 10 antifungals (amphotericin B, flucytosine, fluconazole, voriconazole, posaconazole, micafungin, anidulafungin, caspofungin, and itraconazole) using MICRONAUT-AT tests and manogepix, a new drug, using the microdilution method according to EUCAST. (3)
Results
Overall, most strains were classified as sensitive to amphotericin B and flucytosine (MIC ranges of ≤0.03–1 and ≤0.06–0.125, respectively) and also to echinocandins. However, five isolates expressed high MIC values for all of the tested azoles, indicating cross-resistance. The MIC range for manogepix was 0.001–0.125 mg/L, with an MIC50 of 0.03 mg/L and an MIC90 of 0.06 mg/L. (4)
Conclusions
The occurrence of resistance to azoles may be a concerning problem and therefore should be investigated further. However, the new antifungal manogepix appears to be an interesting new therapeutic option for treating such infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology and Parasitology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
- PhD School of Wroclaw Medical University, Wroclaw Medical University, 50-345 Wroclaw, Poland.
- Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, St. Weigla 12, 53-114 Wroclaw, Poland.
ORCID-Profile: Urszula Nawrot
Förderung
- Wroclaw Medical University
Zitieren
APA
Górzyńska, A., Kondracka, K., Korzeniowska-Kowal, A., & Nawrot, U. (2024). Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens. Pathogens. https://doi.org/10.3390/pathogens13030248
Vancouver
Górzyńska A, Kondracka K, Korzeniowska-Kowal A, Nawrot U. Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens. Pathogens. 2024. doi:10.3390/pathogens13030248
BibTeX
@article{Grzyska2024,
author = {Górzyńska, Aleksandra and Kondracka, Kamila and Korzeniowska-Kowal, Agnieszka and Nawrot, Urszula},
title = {Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13030248}
}
EUVIMED